Latest Insider Transactions at Neurocrine Biosciences Inc (NBIX)
This section provides a real-time view of insider transactions for Neurocrine Biosciences Inc (NBIX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEUROCRINE BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEUROCRINE BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 10
2022
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-11.01%
|
$194,768
$74.5 P/Share
|
|
Jan 05
2022
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,266
-21.21%
|
$2,402,610
$85.5 P/Share
|
|
Jan 05
2022
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,266
+17.5%
|
$226,128
$8.66 P/Share
|
|
Dec 14
2021
|
Stephen A Sherwin Director |
SELL
Bona fide gift
|
Direct |
2,000
-7.39%
|
-
|
|
Dec 10
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
120
-0.35%
|
-
|
|
Dec 01
2021
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,645
-9.14%
|
$134,890
$82.59 P/Share
|
|
Oct 07
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
SELL
Open market or private sale
|
Direct |
8,000
-4.62%
|
$832,000
$104.8 P/Share
|
|
Oct 07
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.42%
|
$215,000
$43.24 P/Share
|
|
Oct 07
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.34%
|
$525,000
$105.06 P/Share
|
|
Oct 04
2021
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
987
-6.24%
|
$99,687
$101.73 P/Share
|
|
Aug 16
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,628
-26.5%
|
$500,892
$89.62 P/Share
|
|
Jul 27
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
16,709
-51.4%
|
$1,553,937
$93.8 P/Share
|
|
Jun 10
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.47%
|
$1,000,000
$100.27 P/Share
|
|
Feb 10
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
1,700
-2.54%
|
$202,300
$119.95 P/Share
|
|
Feb 10
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+2.47%
|
$59,500
$35.99 P/Share
|
|
Feb 09
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
36,194
-20.68%
|
$4,198,504
$116.64 P/Share
|
|
Feb 09
2021
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,194
+15.09%
|
$1,266,790
$35.99 P/Share
|
|
Feb 08
2021
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,363
-6.05%
|
$274,108
$116.75 P/Share
|
|
Feb 08
2021
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,910
-9.17%
|
$337,560
$116.83 P/Share
|
|
Feb 08
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,407
-3.28%
|
$395,212
$116.72 P/Share
|
|
Feb 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,466
-0.77%
|
$1,214,056
$116.75 P/Share
|
|
Feb 08
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
SELL
Open market or private sale
|
Direct |
2,708
-1.06%
|
$314,128
$116.69 P/Share
|
|
Feb 08
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
3,261
-3.32%
|
$378,276
$116.83 P/Share
|
|
Feb 08
2021
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,338
-4.71%
|
$155,208
$116.74 P/Share
|
|
Feb 08
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,270
-6.67%
|
$495,320
$116.83 P/Share
|
|
Feb 08
2021
|
Haig P. Bozigian Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,842
-0.81%
|
$445,672
$116.81 P/Share
|
|
Feb 08
2021
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,693
-1.17%
|
$428,388
$116.85 P/Share
|
|
Feb 05
2021
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
605
-1.94%
|
$68,970
$114.05 P/Share
|
|
Feb 05
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,422
-0.54%
|
$276,108
$114.16 P/Share
|
|
Feb 05
2021
|
Dimitri E. Grigoriadis Chief Research Officer |
SELL
Open market or private sale
|
Direct |
605
-0.73%
|
$68,365
$113.76 P/Share
|
|
Feb 05
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
865
-2.83%
|
$98,610
$114.15 P/Share
|
|
Feb 05
2021
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
605
-4.75%
|
$68,365
$113.86 P/Share
|
|
Feb 05
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
809
-4.69%
|
$92,226
$114.03 P/Share
|
|
Feb 05
2021
|
Haig P. Bozigian Chief Development Officer |
SELL
Open market or private sale
|
Direct |
704
-0.46%
|
$79,552
$113.79 P/Share
|
|
Feb 05
2021
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,677
-1.32%
|
$302,501
$113.93 P/Share
|
|
Jan 26
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
400
-1.25%
|
$48,000
$120.0 P/Share
|
|
Jan 26
2021
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+1.83%
|
$12,300
$41.78 P/Share
|
|
Jan 26
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
1,100
-1.86%
|
$130,900
$119.97 P/Share
|
|
Jan 26
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+1.83%
|
$38,500
$35.99 P/Share
|
|
Jan 26
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
400
-0.18%
|
$48,000
$120.0 P/Share
|
|
Jan 25
2021
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,077
-12.92%
|
$609,240
$120.03 P/Share
|
|
Jan 25
2021
|
Eric Benevich Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,477
+14.27%
|
$142,557
$41.78 P/Share
|
|
Jan 25
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
SELL
Open market or private sale
|
Direct |
17,570
-16.48%
|
$2,090,830
$119.97 P/Share
|
|
Jan 25
2021
|
Malcolm Lloyd Smith Chief Integration Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,570
+13.99%
|
$597,380
$34.99 P/Share
|
|
Jan 25
2021
|
Gary A Lyons Director |
SELL
Open market or private sale
|
Direct |
1,600
-0.71%
|
$192,000
$120.03 P/Share
|
|
Jan 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
308,250
-25.87%
|
$33,907,500
$110.22 P/Share
|
|
Jan 08
2021
|
Kevin Charles Gorman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
308,250
+20.54%
|
$2,466,000
$8.66 P/Share
|
|
Jan 08
2021
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-14.24%
|
$292,152
$111.06 P/Share
|
|
Dec 03
2020
|
Stephen A Sherwin Director |
SELL
Bona fide gift
|
Direct |
2,806
-9.4%
|
-
|
|
Dec 01
2020
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,645
-12.52%
|
$154,630
$94.66 P/Share
|